{"schema_version":"secwatch.filing_event.v1","accession":"0000105770-23-000018","form_type":"8-K","ticker":"WST","cik":"0000105770","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2023-04-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.799543+00:00","generated_at":"2026-06-16T07:56:52.629762+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"West Pharma reports Q1 2023 net sales $716.6M, adjusted EPS $1.98; raises full-year guidance","bullets":["Net sales $716.6M (down 0.5% YoY); organic sales growth 2.3%. Reported diluted EPS $1.85 (down 19.2%); adjusted diluted EPS $1.98 (down 13.9%).","Raised FY2023 net sales guidance to $2.965-2.990B from $2.935-2.960B; adjusted EPS guidance to $7.50-7.65 from $7.25-7.40.","Proprietary Products segment net sales $583.1M (down 3.0%); Biologics market unit organic sales declined double-digits due to lower COVID-19 sales.","Operating cash flow $138.1M; free cash flow $56.0M (down 34.4%). Repurchased 183,360 shares for $60.1M at avg price $327.90.","Board approved Q3 2023 dividend $0.19/share payable Aug 2, 2023 to holders of record Jul 26, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000105770-23-000018","json":"https://secwatch.observer/filing/0000105770-23-000018.json","markdown":"https://secwatch.observer/filing/0000105770-23-000018.md","text":"https://secwatch.observer/filing/0000105770-23-000018.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/105770/000010577023000018/0000105770-23-000018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/105770/000010577023000018/wst-20230427.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T07:56:52.629762+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c7fef759cb9ff45210e753e8bb81a38ad692dc45","claim":"WEST PHARMACEUTICAL SERVICES INC reported first-quarter 2023 results: revenue $716.6 million, EPS $1.85. Guidance raised.","evidence_excerpt":"West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the first-quarter 2023 and updated full-year 2023 financial guidance. First-Quarter 2023 Summary (comparisons to prior-year period) • Net sales of $716.6 million declined 0.5%; organic sales growth was 2.3%. • Reported-diluted EPS of $1.85 declined by 19.2%. • Adjusted-diluted EPS of $1.98 declined by 13.9%. • The Company is updating full-year 2023 financial guidance of net sales to a new range of $2.965 billion to $2.990 billion compared to a prior range of $2.935 billion to $2.960 billion. • The Company is updating full-year 2023 financial guidance of adjusted-diluted EPS to a new range of $7.50 to $7.65, compared to a prior range of $7.25 to $7.40.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577023000018/0000105770-23-000018-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first-quarter 2023"},{"label":"Revenue","value":"$716.6 million"},{"label":"EPS","value":"$1.85"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}